Galmed Pharmaceuticals (GLMD) Net Income towards Common Stockholders (2013 - 2020)

Galmed Pharmaceuticals' Net Income towards Common Stockholders history runs 8 years deep, the most recent figure standing at $6.9 million for Q1 2020.

• In Q1 2020, Net Income towards Common Stockholders rose 49.54% year-over-year to $6.9 million; the TTM figure through Dec 2020 stood at $6.9 million (down 60.54% YoY), while the FY2024 annual figure was $1.7 million, up 8.45% from the prior year.
• Net Income towards Common Stockholders was $6.9 million for Q1 2020 at Galmed Pharmaceuticals, down from $8.3 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $8.3 million in Q4 2019 to a low of $809000.0 in Q3 2018.
• Historically, Net Income towards Common Stockholders has averaged $4.0 million across 5 years, with a median of $3.7 million in 2017.
• The sharpest annual moves came in 2018 and 2019: Net Income towards Common Stockholders slumped 71.12% in 2018, then surged 457.97% in 2019.
• A 5-year view of Net Income towards Common Stockholders shows it stood at $4.8 million in 2016, then dropped by 24.49% to $3.6 million in 2017, then grew by 1.7% to $3.7 million in 2018, then surged by 123.58% to $8.3 million in 2019, then retreated by 17.2% to $6.9 million in 2020.
• The last three Net Income towards Common Stockholders figures came in at $6.9 million (Q1 2020), $8.3 million (Q4 2019), and $4.5 million (Q3 2019), per Business Quant data.